Latest Manufacturing News

Page 7 of 335
Ball’s operating performance strengthened in the third quarter, with comparable EPS, operating earnings and global shipments all higher year on year. But a US$475 million noncash pension settlement charge pushed the aluminum packaging group to a US$94 million GAAP loss and cash generation remains thin.
Maxwell Dee
Maxwell Dee
4 Nov 2026
Clever Culture Systems has secured $2.6 million to develop APAS Revolution, a smaller benchtop system aimed at pharmaceutical manufacturers not served by its existing platform. The funding combines a discounted share placement with new debt, while commercial launch is targeted for the first half of 2028.
Victor Sage
Victor Sage
3 Nov 2026
Marine Biomedical has secured US FDA 510(k) clearance for PearlBone, giving Orthocell a clearer path into bone regeneration through its 12% strategic stake and distribution rights. The commercial opportunity is advancing, but revenue, launch timing and definitive distribution arrangements remain undisclosed.
Ada Torres
Ada Torres
3 Nov 2026
Lennox is replacing the head of its Building Climate Solutions segment with an internal executive while retaining the outgoing leader as a strategic adviser through February 2028. The transition preserves customer and leadership continuity, but the filing does not indicate any change to financial guidance.
Maxwell Dee
Maxwell Dee
3 Nov 2026
Clorox delivered a sharp first-quarter rebound, helped by the GOJO acquisition and an easier comparison after last year’s ERP-related inventory drawdown. But rising commodity, manufacturing and logistics costs have pushed its full-year margin assumptions lower, with adjusted earnings now expected nearer the bottom of the unchanged range.
Victor Sage
Victor Sage
3 Nov 2026
Marvell is seeking to absorb Lumentum in a US$115 billion all-stock deal that would unite electrical interconnect, lasers and optical networking under one roof. The companies are pitching a US$550 billion addressable market and more than US$1 billion in annual synergies, but completion remains well into the future and subject to regulatory and shareholder approval.
Victor Sage
Victor Sage
3 Nov 2026
Estée Lauder delivered a sharp rebound in fiscal 2027’s first quarter, with sales, margins and earnings all improving materially. The beauty group has lifted its full-year outlook, although quarterly free cash flow remained negative and the plan still depends on sustained momentum in China, travel retail and fragrance.
Victor Sage
Victor Sage
3 Nov 2026
Noxopharm has secured a $1.5 million placement and agreed to convert $3.78 million of shareholder notes as it prepares to test SOF-SKN in cutaneous lupus patients. The funding eases an immediate cash constraint, but the package also brings substantial dilution and remains partly subject to shareholder approval.
Ada Torres
Ada Torres
2 Nov 2026
Neurizon Therapeutics has secured A$4.3 million through a discounted placement and is seeking another A$2.0 million from eligible shareholders, while redeeming its remaining Obsidian convertible notes. The move removes current note-conversion dilution, but shifts funding risk towards equity holders ahead of a pivotal NUZ-001 trial readout.
Ada Torres
Ada Torres
2 Nov 2026
Nexsen has secured ISO 13485 certification covering the design, development and manufacture of its StrepSure Group B Streptococcus diagnostic. The milestone strengthens the product’s regulatory and manufacturing platform, but does not yet amount to FDA or TGA approval.
Ada Torres
Ada Torres
2 Nov 2026
Environmental Clean Technologies says Xenica has secured a worldwide, non-exclusive Drexel University licence covering selected commercial MXene applications. The deal broadens the potential market beyond defence, but commercial revenue still depends on acquisition completion, repeatable production and customer qualification.
Victor Sage
Victor Sage
2 Nov 2026
Gold Hydrogen has received a $4 million investment commitment from Eric Sprott as the company moves towards final design and procurement of a modular helium plant at Ramsay in South Australia. The institutional placement adds funding, but the proposed plant remains subject to engineering, approvals, reservoir performance and further capital.
Victor Sage
Victor Sage
2 Nov 2026

Browse the archive

Full archive